Goldman Sachs
BIS icon

Goldman Sachs’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Goldman Sachs’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-776
Closed -$214K – 7262
2015
Q1 		$214K Buy
+776
New +$237K ﹤0.01% 5961

Other funds holding BIS

HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
CAM
Chesapeake Asset Management New York $126M AUM 36.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BHA
Beech Hill Advisors New York $200M AUM 25.74% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Goldman Sachs's BIS Position: Q2 2015 in Review

Goldman Sachs sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2015, closing a stake of 776 shares — an estimated $214K sold.

Goldman Sachs first reported a position in BIS in Q1 2015 and held it in 1 quarter. The position peaked at $214K in Q1 2015. 19 funds tracked by Wall St. Rank hold BIS as of Q2 2015.

  • Goldman Sachs reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2015 after selling out during the quarter.
  • Goldman Sachs sold 776 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2015, an estimated $214K.
  • Goldman Sachs first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q1 2015 and held it in 1 quarter.
  • Goldman Sachs's ProShares UltraShort NASDAQ Biotechnology position peaked at $214K in Q1 2015.
  • 19 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2015.

Based on Goldman Sachs's 13F filing for Q2 2015, filed 14 Aug 2015.